Effect of Zoledronic Acid on Femoral Bone Loss Following Total Hip Arthroplasty
Information source: Spokane Joint Replacement Center
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Osteoporosis
Intervention: Zoledronic acid (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Spokane Joint Replacement Center
Summary
In a randomized, double-blind trial, BMD of the operated proximal femur after total hip
replacement measured by dual-energy x-ray absorptiometry (DXA) were compared for up to two
years in patients receiving IV ZOL 5 mg infusion (n = 27) or placebo (IV saline infusion; n
= 24) at two weeks and one year after surgery.
Clinical Details
Official title: Effect of Zoledronic Acid on Femoral Bone Loss Following Total Hip Arthroplasty
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: Bone mineral density
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patients undergoing primary elective total hip replacement
Exclusion Criteria:
- Osteoporosis (BMD ≤-2. 5)
- Trauma to the operated femur, hip revisions, femoral dysplasia, trochanteric
osteotomy, inflammatory arthritis
- Severe renal impairment
- Use of any medications affecting BMD
- Known sensitivity to bisphosphonates
- Severe dental problems, and pregnancy or being able to conceive and not using
reliable birth control methods
Locations and Contacts
Additional Information
Starting date: January 2005
Last updated: January 21, 2015
|